CVR 89563011Public limited company (A/S)Fremstilling af andre fødevarer i.a.n. (108900)LyngeFounded 22 Jun 1984
Compiled by Dandex from the Danish Business Registry (CVR, datacvr.virk.dk), Erhvervsstyrelsen, and annual reports filed in XBRL. Values marked Dandex estimate are computed by Dandex from that data, not registered.
Dandex is Danish Company Data. Connect it once and ask about PARAMEDICAL A/S, or any Danish company, from your assistant, the API or the command line. Answers come from the current record: owners and the ownership network, financials year by year, and the latest registered changes.
Set up DandexEmployees
59
CVR, 2015
Gross profit
32.1M
DKK, annual report 2015
-1.2% on 2014
Result
-2.2M
DKK, annual report 2015
Equity
38.2M
DKK, annual report 2015
Orkla Care A/SCVR 16173592, 100% of capital and votes, until 25 Jan 2016
Christian Holstuntil 25 Jan 2016
No current owner is registered.
CVR 16173592100% of capital and votes4 Sep 2015 to 25 Jan 2016
CVR 31760232100% of capital and votes24 Sep 2008 to 3 Sep 2015
Decided by Dandex from CVR and the filed annual reports, not registered by the company.
Fixed rules decide most of these. The auditor's report, the business model, the revenue model and the activity in its own words are read by a calibrated decision model from the report's text and the purpose clause. Each label links to its definition.
CVR lists no current officers for this company.
Jan 2016, monthly: 52 employees, 48 FTE
Arrow keys move through the periods, Home and End go to the first and the latest, Escape returns to the latest.
| Period | 1997 | 1998 | 1999 | 2000 | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | Q1 2010 | Q2 2010 | Q3 2010 | Q4 2010 | 2011 | 2012 | 2013 | 2014 | Jan 2015 | Feb 2015 | Mar 2015 | Apr 2015 | May 2015 | Jun 2015 | Jul 2015 | Aug 2015 | Sep 2015 | Oct 2015 | Nov 2015 | Dec 2015 | Jan 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Employees | 9 | 9 | 12 | 8 | 7 | 9 | 13 | 54 | 52 | 50 | 54 | 48 | 46 | No count | No count | No count | No count | 40 | 51 | 54 | 56 | 61 | 57 | 60 | 57 | 61 | 60 | 59 | 58 | 61 | 61 | 62 | 61 | 52 |
| FTE | 7 | 7 | 8 | 6 | 6 | 7 | 9 | 47 | 40 | 42 | 46 | 48 | 46 | 46 | 42 | 41 | 39 | 39 | 44 | 50 | 54 | 58 | 55 | 56 | 54 | 56 | 55 | 54 | 53 | 56 | 56 | 56 | 57 | 48 |
| Series | Annual | Annual | Annual | Annual | Annual | Annual | Annual | Annual | Annual | Annual | Annual | Annual | Annual | Quarterly | Quarterly | Quarterly | Quarterly | Annual | Annual | Annual | Annual | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly | Monthly |
The legal entity's headcount in CVR, not the annual report's average, which may cover a group.
Source: CVR, latest Jan 2016, published 23 Mar 2016.
The company's own figures, in DKK, from the annual reports filed in XBRL.
2015, DKK: Gross profit 32.1M, Operating profit -2.8M, Result for the year -2.2M
Arrow keys move through the years, Home and End go to the first and the latest, Escape returns to the latest.
2015, DKK: Total assets 55.6M, Equity 38.2M
Arrow keys move through the years, Home and End go to the first and the latest, Escape returns to the latest.
| DKK thousands | 2011 | 2012 | 2013 | 2014 | 2015 |
|---|---|---|---|---|---|
| Gross profit | Not reported | Not reported | Not reported | 32,551 | 32,146 |
| Operating profit | Not reported | Not reported | -2,181 | +1,512 | -2,810 |
| Result for the year | Not reported | Not reported | -1,535 | +1,077 | -2,250 |
| Equity | Not reported | Not reported | 39,360 | 40,437 | 38,187 |
| Total assets | Not reported | Not reported | 55,823 | 51,449 | 55,649 |
| Credit metrics (Dandex calculations) | |||||
| Gross profit growth (vækst i bruttofortjeneste) | Not reported | Not reported | Not reportednote 1 | 24.9% | -1.2% |
| EBITDA | Not reported | Not reported | 1,812 | 5,573 | 1,362 |
| EBITDA / gross profit (EBITDA i procent af bruttofortjenesten)Pro: EBITDA / gross profit (EBITDA i procent af bruttofortjenesten) is in the Pro plan, see pricingEBITDA as a share of gross profit. | Pro: EBITDA / gross profit (EBITDA i procent af bruttofortjenesten) is in the Pro plan, see pricingEBITDA as a share of gross profit. | ||||
| Net interest-bearing debt (NIBD, nettorentebærende gæld)Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. | Pro: Net interest-bearing debt (NIBD, nettorentebærende gæld) is in the Pro plan, see pricingInterest-bearing debt less cash and current securities; negative is net cash. | ||||
| Gearing, NIBD / EBITDAPro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. | Pro: Gearing, NIBD / EBITDA is in the Pro plan, see pricingNet interest-bearing debt over EBITDA: the years of earnings the debt takes. | ||||
| Interest coverage (rentedækning)Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. | Pro: Interest coverage (rentedækning) is in the Pro plan, see pricingEBIT over finance expenses: how many times earnings cover the interest. | ||||
| Adjusted equity ratio (justeret soliditetsgrad)Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. | Pro: Adjusted equity ratio (justeret soliditetsgrad) is in the Pro plan, see pricingAdjusted equity as a share of total assets on the same basis. | ||||
| ROIC (afkast af investeret kapital)Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. | Pro: ROIC (afkast af investeret kapital) is in the Pro plan, see pricingReturn on invested capital: EBIT after tax over equity plus net debt. | ||||
| Capex (investeringer i anlægsaktiver) | Not reported | Not reported | 1,881note 2 | 3,369note 2 | 5,441 |
| Capex % of sales (investeringer i procent af omsætningen)Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. | Pro: Capex % of sales (investeringer i procent af omsætningen) is in the Pro plan, see pricingCapex as a share of revenue. | ||||
| FCFF / EBITDA (pengestrømskonvertering)Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. | Pro: FCFF / EBITDA (pengestrømskonvertering) is in the Pro plan, see pricingFree cash flow to the firm as a share of EBITDA. | ||||
2013: The 2014 report shows 2013 in amounts a thousand times larger than the 2013 report does, and this filing states its share capital a thousand times smaller than CVR registers it, so it tagged its amounts in the wrong unit. Dandex multiplied them by a thousand.
Credit metrics are Dandex calculations, not filed values; grey figures are estimates with a note. Definitions. Revenue-based rows are empty: the company reports gross profit only (bruttofortjeneste), which class B filers may.
How each credit metric is calculated:
No changes since Dandex began following this company. For announcements from before then, see Registrations.
Pro: Signals (signaler) are in the Pro plan, see pricingChanges worth a look, raised from the registry and new annual reports.
New leadership (nyt lederskab), New company (ny virksomhed), Ownership change (ejerskifte), Relocation (flytning), Growth surge (vækstspurt), Headcount decline (nedgang i ansatte), Restructuring (omstrukturering), Industry change (brancheskift), Board change (bestyrelsesændring), Dissolution (ophør), Distress warning (risikoadvarsel), Fund investment (fondsinvestering), Fund exit (fondsexit), Fund board seat (fondsbestyrelsespost).
What Pro holds for PARAMEDICAL A/S:
Have Pro? Sign in.
Amounts in DKK.
| Date | Change | Cash price | Paid in | Implied value | Capital after |
|---|---|---|---|---|---|
| IncreaseMergerPaid in 3,741,528 | None | 3,741,528 | None | 2,530,000 | |
| IncreaseBonus issue from reserves | None | None | None | 2,250,000 | |
| FoundingNot read from the announcement | None | None | None | 450,000 |
Source: Erhvervsstyrelsen's announcements, shown where the amounts add up to the registered capital.
Merger (fusion), as the ceasing company (ophørende selskab)
Merger (fusion), as the continuing company (fortsættende selskab)
Merger (fusion), as the continuing company (fortsættende selskab)
Source: CVR, read 19 Nov 2026.
Counts include corrections, and an audit firm that re-registered under a new entity.
Source: CVR, read 19 Nov 2026.
31 registrations, as published by Erhvervsstyrelsen. People's street addresses are cut to postcode and city.
Erhvervsstyrelsen har modtaget fusionsplan for den påtænkte fusion mellem CVR-nummer: 16173592 Orkla Care A/S (fortsættende), der tillige driver virksomhed under navnene VITALIA A/S, NUTRICARE A/S, DROGEN'S PHARMA A/S, GERIMAX EXTREME ENERGY A/S, DANSK VITAMIN INDUSTRI A/S, DANSK DROGE A/S, DD SPORT A/S, GLOBAL A/S, MAXIM A/S, MAXIM INTERNATIONAL A/S, MAXIM DANMARK A/S, PHARMA-VINCI A/S, DANSK FARMASAN A/S, PHARMA-VINCI HOLDING A/S, AXELLUS A/S, W. Ratje Frøskaller A/S, Husk Products A/S, Orkla Health A/S, CVR-nummer: 62565810 CEDERROTH A/S (ophørende) og CVR-nummer: 89563011 PARAMEDICAL A/S (ophørende), der tillige driver virksomhed under navnene PARAPHARM A/S, CEDERROTH INTERNATIONAL PRODUCTION PARAMEDICAL A/S, CEDERROTH PARAMEDICAL A/S.
Der er endvidere modtaget erklæring fra vurderingsmændene om, at kreditorerne i CVR-nummer: 16173592 Orkla Care A/S, CVR-nummer: 62565810 CEDERROTH A/S og CVR-nummer: 89563011 PARAMEDICAL A/S må antages at være tilstrækkeligt sikrede efter fusionen.
CVR-nummer:
89563011.
NAVN:
PARAMEDICAL A/S.
Adresse: Vassingerødvej 3-7, 3540 Lynge.
Kommune: Allerød.
Bestyrelse:
Fratrådte:
Christian Holst, den 31.08.2015, Eva Margareta Jansson, den 31.08.2015, Lars Mikael Nordin (formand), den 31.08.2015.
Tiltrådte:
Jan Roar Nordby, den 31.08.2015, Johannes Arbo Høeg (formand), den 31.08.2015, Stig Ebert Nilssen, den 31.08.2015.
Direktion:
Fratrådte:
.
Revision:
Fratrådte:
KPMG P/S, den 31.08.2015.
Tiltrådte:
CVR-NR. 30700228 ERNST & YOUNG Godkendt Revisionspartnerselskab, Osvald Helmuths Vej 4, 2000 Frederiksberg, den 31.08.2015.
Bestyrelse:
Udtrådt af bestyrelsen:
Leif Gustav Wahlgren, den 15.04.2013.
Indtrådt i bestyrelsen:
Koncernchef Lars Mikael Nordin (formand), den 15.04.2013.
Bestyrelse:
Udtrådt af bestyrelsen:
Finn Esbech, den 31.08.2012.
Indtrådt i bestyrelsen:
Adm. direktør Christian Holst, den 01.09.2012.
Direktion:
Udtrådt af direktionen:
Finn Esbech, den 31.08.2012.
Indtrådt i direktionen:
Adm. direktør Christian Holst (adm. dir), den 01.09.2012.
Vedtægter ændret:
12.05.2011.
Nyt binavn: CEDERROTH PARAMEDICAL A/S.
Slettet binavn: FLEMMING NØRGAARD LONGO VITAL A/S.
Vedtægter ændret:
11.05.2010.
Selskabet tegnes af to bestyrelsesmedlemmer i forening eller af et bestyrelsesmedlem i forening med en direktør.
Vedtægter ændret:
21.04.2009.
Regnskabsår ændret til:
01.01 - 31.12.
Omlægningsperiode:
01.10.2008 - 31.12.2009.
Revision:
Udtrådt af revisionen:
KPMG C. Jespersen Statsautoriseret Revisionsinteressentskab, den 20.01.2009.
Indtrådt i revisionen:
CVR-NR. 30700228 KPMG STATSAUTORISERET REVISIONSPARTNERSELSKAB, Borups Allé 177, 2400 København NV, den 20.01.2009.
Bestyrelse:
Udtrådt af bestyrelsen:
Sven Ivar Fonn, den 14.04.2008.
Indtrådt i bestyrelsen:
Eva Margareta Jansson, den 14.04.2008.
Vedtægter ændret:
26.05.2006.
Nyt binavn: FLEMMING NØRGAARD LONGO VITAL A/S (PARAMEDICAL A/S).
Kapitalforhøjelse:
kr. 280.000,00 indbetalt ved fusion, kurs 1.336,26.
Kapitalen udgør herefter kr. 2.530.000,00.
Selskabet er fusioneret med CVR-NR. 87330214 FLEMMING NØRGAARD, LONGO VITAL ApS, der samtidig er opløst.
Erhvervs- og Selskabsstyrelsen har modtaget
fusionsplan i henhold til aktieselskabslovens § 134 a og
anpartsselskabslovens § 65 for fusion mellem
CVR-NR. 89563011 PARAMEDICAL A/S. der tillige driver virksomhed under navnene PARAPHARM A/S (PARAMEDICAL A/S), CEDERROTH INTERNATIONAL PRODUCTION PARAMEDICAL A/S (PARAMEDICAL A/S).
CVR-NR. 87330214 FLEMMING NØRGAARD, LONGO VITAL ApS.
Endvidere er modtaget erklæring fra
vurderingsmændene i henhold til aktieselskabslovens §
134 c, stk. 4 og anpartsselskabslovens § 65.
Vedtægter ændret:
20.12.2005.
Nyt binavn: CEDERROTH INTERNATIONAL PRODUCTION PARAMEDICAL A/S (PARAMEDICAL A/S).
Slettet binavn: FLEMMING NØRGAARD PARAMEDICAL A/S (PARAMEDICAL A/S).
Selskabet tegnes af medlemmer af bestyrelsen, to i forening eller af en direktør.
Vedtægter ændret:
25.05.2005.
Regnskabsår ændret til:
01.10 - 30.09.
Omlægningsperiode:
01.01.2005 - 30.09.2005.
Vedtægter ændret:
22.02.2005.
Ny adresse:
Vassingerødvej 3-7, 3540 Lynge.
Ny kommune:
Allerød.
Bestyrelse:
Udtrådt af bestyrelsen:
Henrik Steen Andersen, den 07.01.2005, Hans Holm, den 07.01.2005, Tage Jarlbo, den 07.01.2005, Leif Rasmussen, den 07.01.2005.
Indtrådt i bestyrelsen:
Direktør Finn Esbech, den 07.01.2005, Finansdirektør Sven Ivar Fonn, den 07.01.2005, President CEO Leif Gustav Wahlgren, den 07.01.2005.
Direktion:
Udtrådt af direktionen:
Claus Nørgaard, den 07.01.2005.
Indtrådt i direktionen:
Direktør Finn Esbech (adm. dir), den 07.01.2005.
Revision:
Udtrådt af revisionen:
ERNST & YOUNG STATSAUTORISERET REVISIONSAKTIESELSKAB, den 07.01.2005.
Indtrådt i revisionen:
KPMG C. Jespersen Statsautoriseret Revisionsinteressentskab, Borups Alle 177, postboks 250, 2000 Frederiksberg, den 07.01.2005.
Vedtægter ændret:
19.06.2003.
Nyt binavn: PARAPHARM A/S (PARAMEDICAL A/S).
Selskabet fusioneret med CVR-NR. 78858818 PARAPHARM A/S, der samtidig er opløst.
Erhvervs- og Selskabsstyrelsen har modtaget
fusionsplan i henhold til aktieselskabslovens § 134 a
for fusion mellem
CVR-NR. 89563011 PARAMEDICAL A/S. der tillige driver virksomhed under navnet FLEMMING NØRGAARD PARAMEDICAL A/S (PARAMEDICAL A/S).
CVR-NR. 78858818 PARAPHARM A/S.
Endvidere er modtaget erklæring fra
vurderingsmændene i henhold til aktieselskabslovens §
134 c, stk. 4.
Bestyrelse:
Udtrådt af bestyrelsen:
Carsten Saxild Hjorth, den 08.06.2000, Claus Nørgaard, den 08.06.2000, Kirsten Paulsen, den 08.06.2000.
Indtrådt i bestyrelsen:
Direktør Hans Jørgen Bechsøfft, den 08.06.2000, Fhv. bankdir Hans Holm, den 08.06.2000, Direktør Tage Jarlbo, den 08.06.2000.
Bestyrelse:
Indtrådt i bestyrelsen:
Direktør Carsten Saxild Hjorth, den 26.08.1997, Salgs- og marketingsdirektør Jens Bo Olesen, den 26.08.1997.
Bestyrelse:
Udtrådt af bestyrelsen:
Jens Christian Hesse Rasmussen, den 25.06.1997.
Indtrådt i bestyrelsen:
Advokat Henrik Steen Andersen, den 25.06.1997.
Bestyrelse:
Udtrådt af bestyrelsen:
Jørgen Erichsen Hoffmeyer, den 21.05.1996.
Indtrådt i bestyrelsen:
Advokat Jens Christian Hesse Rasmussen (formand), den 21.05.1996.
Vedtægter ændret:
04.08.1993.
Kapitalforhøjelse:
kr. 1.800.000,00 indbetalt ved overførte reserver / overskud, kurs 100,00
Kapitalen udgør herefter kr. 2.250.000,00
Revision:
Udtrådt af revisionen:
REG.NR. A/S66233 AKTIESELSKABET GEER & LYNGVIG, STATSAUTORISEREDE REVISORER
Indtrådt i revisionen:
ERNST & YOUNG A/S, Østergade 11, 4000 Roskilde
Bestyrelse:
Udtrådt af bestyrelsen:
Revision:
Udtrådt af revisionen:
Revisionsfirmaet E. Lundgaard Andersen
Indtrådt i revisionen:
GEER & LYNGVIG A/S, Haraldsborgvej 20, 4000 Roskilde
Binavn:
FLEMMING NØRGAARD PARAMEDICAL A/S (PARAMEDICAL A/S)
Stiftelsesdato:
22.06.1984
Seneste vedtægtsdato:
22.03.1984
Kapital:
kr. 450.000,00
Indbetalingsmåde:
kontant/i værdier kr. 450.000,00 til kurs 100,0
Bestyrelse:
Landsretssagfører Jørgen Erichsen Hoffmeyer, Ingeniør Claus Nørgaard, Direktør Jens Bo Olesen, Fru Kirsten Paulsen
Direktion:
Ingeniør Claus Nørgaard
Selskabet tegnes af to medlemmer af
bestyrelsen i forening eller af en direktør
alene
Revision:
Revisionsfirmaet E. Lundgaard Andersen, 1264 København K
Første regnskabsår:
00.00 - 00.00
Regnskabsår:
01.01 - 31.12
P-number 1002563795Vassingerødvej 3, 3540 Lynge
P-number 1002821644Høeghsmindevej 83, 2820 Gentofte
P-number 1010181255Vassingerødvej 3, 3540 Lynge